Citations

Mayo Clinic

Showing 10 of 108523 citations.

Updates in the Care of Women in Menopause
Wang, Annie Y., Files, Julia A. , Kransdorf, Lisa N , Kransdorf, Lisa N. , Wang, Annie Y.

Journal of Women's Health | July 9, 2024 | Volume: 33 | Issue: 9 | Pages: 1283-1287

10.1089/jwh.2024.0644 | PMID 38979624 Get It

Athlete-Specific Considerations of Cartilage Injuries
Meta, Fabien , Clark, Sean C. , Saris, Daniël B.F. , Tagliero, Adam J. , Hevesi, Mario , Krych, Aaron J.

Sports Medicine and Arthroscopy Review | July 9, 2024 | Volume: 32 | Issue: 2 | Pages: 60-67

10.1097/jsa.0000000000000379 | PMID 38978199 Get It

Cartilage injuries can present in a diverse setting of anatomic locations, with varying severity, and can impact athletes of all ages and competition levels. Moreover, the timing of when an injury presents introduces an additional dimension to treatment decision-making. Frequently, the level of competition, in conjunction with career trajectory and short-term and long-term athlete goals, will dictate whether a temporary or definitive treatment strategy is ideal. Although indicating the correct therapeutic regimen may prove challenging, understanding the athlete-specific considerations can be essential to meeting the goals of the athlete and other stakeholders involved in the athlete’s career. The purpose of this review is to comprehensively present the deliberations a treating physician must consider in managing cartilage injuries within a spectrum of athletic levels ranging from youth to professional levels, with a secondary focus on the presentation of temporizing treatment strategies and associated outcomes.
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson, Sindhu R. , Bernstein, Elana J. , Bolster, Marcy B. , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Allen, Aberdeen, Buckley, Lenore M. , Corwin, Douglas S., Dellaripa, Paul F. , Domsic, Robyn T. , Doyle, Tracy J. , Falardeau, Catherine Marie, Gibbons, Fiona K., Johnson, Cheilonda , Lim, Sian Yik , McMahan, Zsuzsanna H. , Merck, Samantha J. , Nesbitt, Kiana, Scholand, Mary Beth , Shapiro, Lee , Sharkey, Christine D., Summer, Ross , Varga, John , Warrier, Anil, Agarwal, Sandeep K. , Antin‐Ozerkis, Danielle, Chowdhary, Vaidehi , D’Amico, Jane E. Dematte, Hallowell, Robert W. , Hinze, Alicia M. , Injean, Patil, Jiwrajka, Nikhil , Joerns, Elena K. , Lee, Joyce , Natalini, Jake G. , Saygın, Didem , Lakin, Kimberly S. , Solomon, Joshua J. , Turgunbaev, Marat, Vaseer, Samera, Turner, Amy S. , Uhl, Stacey , Ivlev, Ilya , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Assassi, Shervin , Buckley, Lenore , Dellaripa, Paul F , Domsic, Robyn T , Frech, Tracy M , Hinchcliff, Monique , Lim, Sian Yik , McMahan, Zsuzsanna H , Hinze, Alicia M , Jiwrajka, Nikhil , Joerns, Elena K , McDermott, Gregory , Natalini, Jake G , Sparks, Jeffrey A , Turner, Amy S , Ivlev, Ilya , Bernstein, Elana J , Lee, Joyce S , Chung, Jonathan Hero , Danoff, Sonye Karen , Guyatt, Gordon , Mirza, Reza Donald , Assassi, Shervin , Chami, Hassan A. , Frech, Tracy , Kanne, Jeffrey P. , Kim, John S. , Matson, Scott M. , Bemiss, B. , Makol, Ashima , McDermott, Gregory C , Oldham, Justin M , Singh, Namrata , Sparks, Jeffrey A.

Arthritis & Rheumatology | July 9, 2024 | Volume: 76 | Issue: 8 | Pages: 1182-1200

10.1002/art.42861 | PMID 38978310 Get It

Objective We provide evidence‐based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs). Methods We developed clinically relevant population, intervention, comparator, and outcomes questions. A systematic literature review was then performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A panel of clinicians and patients reached consensus on the direction and strength of the recommendations. Results Thirty‐five recommendations were generated (including two strong recommendations) for first‐line SARD‐ILD treatment, treatment of SARD‐ILD progression despite first‐line ILD therapy, and treatment of rapidly progressive ILD. The strong recommendations were against using glucocorticoids in systemic sclerosis–ILD as a first‐line ILD therapy and after ILD progression. Otherwise, glucocorticoids are conditionally recommended for first‐line ILD treatment in all other SARDs. Conclusion This clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the treatment of ILD in people with SARDs.
Reduction in Balloon Pump Size Reduces Axillary Intraaortic Balloon Pump Failure Risk
Inglis, Sara S. , Kanwar, Ardaas, Bonilla, Hilda Mariana Gonzalez , Singh, Swaiman, Pearson, Jennifer Y. , Abbas, Mohsin, Folkens, Lori A., Ou, Narith N., Spencer, Philip J. , Villavicencio, Mauricio A. , Clavell, Alfredo L. , Rosenbaum, Andrew , Bonilla, Hilda Gonzalez, Rosenbaum, Andrew N , Inglis, Sara S , Frantz, Robert P. , Behfar, Atta

ASAIO Journal | July 8, 2024 | Volume: 71 | Issue: 1 | Pages: 68-74

10.1097/mat.0000000000002268 | PMID 38976860 Get It

Axillary artery intra-aortic balloon pump (axIABP) placement has been implemented as a bridging solution before heart transplantation. This study evaluates complications associated with axIABP support and describes an approach to minimize adverse events. We previously described a percutaneous approach for axIABP placement. However, patients receiving axIABP between September 1, 2017, and September 26, 2019 (n = 32) demonstrated a high rate of balloon pump malfunction (8/32; 25%) and other complications (totaling 15/32; 47%). Sixty-four patients were sequentially treated under a revised protocol. Compared to the initial cohort, no significant differences in demographics were noted. A significant reduction in rate of balloon malfunction (8/32, 25% vs. 1/64, 2%; p < 0.001) and total complications (15/32, 47% vs. 10/64, 16%; p = 0.0025) during the period of support were noted after intervention. Subsequent analysis of total complications per device size (40 vs. ≤ 34 ml balloon) revealed significantly reduced complications in patients with smaller devices (40% vs. 13%, respectively; p = 0.0022). This study provides guidelines to limit complications in patients supported with axIABP, facilitating a protracted period of bridging support.
PET Imaging of Differentiated Thyroid Cancer with TSHR-Targeted [89Zr]Zr-TR1402
Gimblet, Grayson R. , Whitt, Jason, Reddy, Pratheek, Copland, John Al, Jaskula‐Sztul, Renata , Kenderian, Saad S. , Houson, Hailey A. , Reddy, Pratheek, Szkudlinski, Mariusz W. , Lapi, Suzanne E.

Molecular Pharmaceutics | July 8, 2024 | Volume: 21 | Issue: 8 | Pages: 3889-3896

10.1021/acs.molpharmaceut.4c00224 | PMID 38976794 Get It

Sex differences in treatment of familial hypercholesterolaemia: a meta-analysis
Iatan, Iulia , Ruel, Isabelle L. , Guérin, Amanda , Hales, Lindsay , Coutinho, Thais , Genest, Jacques , Ruel, Isabelle , Coutinho, Thais D. , Genest, Jacques , Akioyamen, Leo E. , Brunham, Liam R.

European Heart Journal | July 8, 2024 | Volume: 45 | Issue: 35 | Pages: 3231-3250

10.1093/eurheartj/ehae417 | PMID 38976372 Get It

Abstract Background and Aims Familial hypercholesterolaemia (FH) is a highly prevalent monogenic disorder characterized by elevated LDL cholesterol (LDL-C) levels and premature atherosclerotic cardiovascular disease. Sex disparities in diagnosis, lipid-lowering therapy, and achieved lipid levels have emerged worldwide, resulting in barriers to care in FH. A systematic review was performed to investigate sex-related disparities in treatment, response, and lipid target achievement in FH (PROSPERO, CRD42022353297). Methods MEDLINE, Embase, The Cochrane library, PubMed, Scopus, PsycInfo, and grey literature databases were searched from inception to 26 April 2023. Records were eligible if they described sex differences in the treatment of adults with FH. Results Of 4432 publications reviewed, 133 met our eligibility criteria. In 16 interventional clinical trials (eight randomized and eight non-randomized; 1840 participants, 49.4% females), there were no differences between males and females in response to fixed doses of lipid-lowering therapy, suggesting that sex was not a determinant of response. Meta-analysis of 25 real-world observational studies (129 441 participants, 53.4% females) found that females were less likely to be on lipid-lowering therapy compared with males (odds ratio .74, 95% confidence interval .66–.85). Importantly, females were less likely to reach an LDL-C &lt; 2.5 mmol/L (odds ratio .85, 95% confidence interval .74–.97). Similarly, treated LDL-C levels were higher in females. Despite this, male sex was associated with a two-fold greater relative risk of major adverse cardiovascular events including myocardial infarction, atherosclerotic cardiovascular disease, and cardiovascular mortality. Conclusions Females with FH were less likely to be treated intensively and to reach guideline-recommended LDL-C targets. This sex bias represents a surmountable barrier to clinical care.
A Pragmatic Approach to Assessing Supervisor Leadership Capability to Support Healthcare Worker Well-Being
Satele, Daniel , Dyrbye, Liselotte N. , West, Colin P.

Journal of Healthcare Management | July 8, 2024 | Volume: 69 | Issue: 4 | Pages: 280-295

10.1097/jhm-d-23-00137 | PMID 38976788 Get It

Goal: We sought to build upon previous studies that have demonstrated how healthcare workers’ ratings of their immediate supervisor’s leadership capabilities relate to their well-being and job satisfaction. Methods: In 2022, we analyzed cross-sectional data from 1,780 physicians and 39,896 allied health professionals (collected in 2017) and 729 residents (collected in 2019), as well as longitudinal data from 1,632 physicians (collected from 2015 to 2017), to identify a psychometrically strong, broadly applicable, actionable, and low-burden approach to assessing supervisor leadership capability to support healthcare worker well-being. Principal Findings: The magnitude of association between our 1-, 2-, 3-, and 9-item leadership indexes and burnout, and between our 1-, 2-, 3-, and 9-item leadership indexes and satisfaction with the organization were similar to each other in the cross-sectional and longitudinal cohorts and across diverse groups of healthcare workers, including physicians, residents, and allied health professionals. The likelihood ratio for a high leadership score increased with an increasing score for each leadership measure. The area under the receiver operating characteristic curve for the 1-, 2-, and 3-item measures for a high leadership score was 0.9349, 0.9672, and 0.9819, respectively. Practical Applications: A single item assessing perceptions of leadership capability efficiently provides useful information about leadership qualities of healthcare workers’ immediate supervisors. The inclusion of this item in healthcare worker surveys may be useful for evaluating interventions and galvanizing organizational action to support healthcare worker well-being.
Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study
Kusne, Yael , Finke, Christy M. , Elsabbagh, Zaid , McCue, Shaylene , Hobday, Timothy J. , Starr, Jason S. , Bekaii‐Saab, Tanios , Hálfdánarson, Þorvarður R. , Patnaik, Mrinal M. , Hobday, Timothy J , Starr, Jason S , Bekaii-Saab, Tanios S , Halfdanarson, Thorvardur R , Patnaik, Mrinal , Ou, Fang-Shu , Sonbol, Mohamad B , Lasho, Terra L. , Ou, Fang‐Shu , Sonbol, Mohamad Bassam

JCO Precision Oncology | July 8, 2024 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/po.24.00143 | PMID 38976813 Get It

PURPOSE Thrombocytopenia is a relatively common dose-limiting toxicity during peptide receptor radionuclide therapy (PRRT) in patients with NET. Although uncommon, some patients develop persistent cytopenia and eventually therapy-related myeloid neoplasm (t-MN), which has a dismal prognosis. As the indications for PRRT are expanding, it is important to investigate factors that may predict cytopenias during/after PRRT. We prospectively evaluated the prevalence of clonal hematopoiesis (CH) and cytopenia in patients with NET undergoing PRRT. MATERIALS AND METHODS Patients with metastatic NET with plan to receive four cycles of lutetium-177 were enrolled. CH was evaluated before PRRT using a panel of 220 genes with a targeted depth of ≥1,000×. Patients were followed during PRRT and every 3 months thereafter. RESULTS Of 37 patients enrolled, the median age was 68 years and 51.4% were male. Previous treatment exposures included alkylating agents in 30%, platinum agents in 8%, and external radiation in 13%. CH was detected in 35.1% using a variant allele frequency (VAF) cutoff of ≥2% and 45.9% with a VAF of ≥1%. The most common mutations were in age-related genes ( DNMT3A, TET2). CH was not associated with anemia or neutropenia; however, it was associated with lower platelet count at baseline and more time spent in a thrombocytopenic state during/after PRRT. Five patients had bone marrow biopsies (BMBs) because of sustained hematologic dysfunction post-PRRT, and of those, diagnoses included clonal cytopenia of undetermined significance (CCUS) in three and idiopathic cytopenia of undetermined significance (ICUS) in two. CONCLUSION CH is present in 35.1% of patients with NET and is associated with thrombocytopenia risk during PRRT. Future studies with long-term follow-up will delineate whether CH might be a predictor for higher risk of t-MN after PRRT.
Association of human interpretable features derived from pancreatic ductal adenocarcinoma pathology slides with disease-free survival.
Siddiqui, Zafar, Haemmerle, Robert , Carr, Ryan M

Journal of Clinical Oncology | July 8, 2024 | Volume: 42 | Issue: 16_suppl | Pages: e16368-e16368

10.1200/jco.2024.42.16_suppl.e16368 Get It

e16368 Background: Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second cause of cancer death in the US by 2040. For the minority of patients who are candidates for curative-intent surgical resection, a neoadjuvant approach with chemotherapy or chemotherapy followed by chemoradiotherapy (chemoRT) has become the standard of care. The tumor microenvironment (TME) has been recognized as a key factor in therapeutic resistance and disease progression. This study aims to explore the prognostic value of human-interpretable machine learning image features (HIFs) derived from whole-slide H&E images. Methods: Consecutive PDAC patients who underwent neoadjuvant therapy followed by surgical resection were studied in this single-institution retrospective study. Clinical variables collected include tumor site (head/body/tail), surgery extent, histology, sex, age at diagnosis, grade, treatment response (4-point scale), LVI, PNI, resection margin status, pathological TNM staging, number of lymph nodes removed/positive, neoadjuvant strategy (chemotherapy vs chemoRT), and number of neoadjuvant chemo cycles. These factors were analyzed with a multivariable Cox proportional hazards model for disease-free survival (DFS) after surgery. Additionally, 420 human-interpretable image features (HIFs) derived from a commercial machine learning software were analyzed with a univariable Cox model on a binary outcome of 1-yr DFS, applying a Bonferroni correction for multiple comparisons to identify significant predictors. Results: Increased neoadjuvant chemotherapy cycles (HR = 0.62, p = 0.001, [median: 8, IQR: 6-12]) and receipt of combination neoadjuvant therapy (HR = 0.15, p = 0.020, [29% chemo, 71% +chemoRT]) exhibited a protective effect in the multivariable DFS model. 3 HIFs quantifying immune cells and macrophages within the cancerous tissue and its stroma were associated with an improved probability of 1-year DFS. Conclusions: In addition to clinical factors, HIFs may offer valuable insights into the tumor microenvironment's influence on PDAC progression, paving the way for improved prognostic models and therapeutic strategies. Future work will integrate clinical predictors with HIFs in a combined model.
Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.
Weiskittel, Taylor M. , Koukol, Austin , Kellinger, Caroline, Zhang, Leiqing , Carneiro, Benedito A. , El‐Deiry, Wafik S. , Mazar, Andrew P. , Li, Hu , Ugolkov, Andrey

Journal of Clinical Oncology | July 8, 2024 | Volume: 42 | Issue: 16_suppl | Pages: e16331-e16331

10.1200/jco.2024.42.16_suppl.e16331 Get It

e16331 Background: Elraglusib (9-ING-41), a potent and selective GSK-3 inhibitor, is a targeted anticancer agent with clinical activity in phase 1 trial and undergoing clinical development for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib (9-ING-41) displayed immune-modulatory activity in preclinical models and modulation of serum cytokine profile in clinical specimens. Here, we investigated the correlation between plasma levels of cytokines/chemokines/soluble cell receptors/growth factors (CCSG) and clinical outcomes of patients with mPDAC treated with elraglusib and gemcitabine/nab-paclitaxel (GnP) in an exploratory study. Methods: CCSGs were evaluated in the pre-dose plasma samples of patients with newly diagnosed mPDAC enrolled in the 1801 phase 2 study (NCT03678883) treated with GnP (n = 13) or elraglusib/GnP (n = 32). Using a Luminex immunoassay, 40 CCSGs were screened as predictive biomarkers of median overall survival (mOS) in the elraglusib/GnP arm using 5-fold cross-validation and maximally selected rank statistic cutpoint determination. A subset of CCSGs (n = 10) was remeasured using an MSD immunoassay with greater sensitivity. Maximally selected rank statistic cutpoint determinations were conducted using MSD results for elraglusib/GnP samples with mOS and median progression free survival (mPFS). P values < 0.05 were considered statistically significant. Results: Luminex screening revealed several CCSGs significantly stratified elraglusib/GnP patients by mOS. IL-6 and IL-8 were identified as top candidates with stable and significant results on cross-validation. Using the MSD assay, both were confirmed to stratify elraglusib/GnP patients by OS and extended to analyze PFS. Low level of IL-8 conferred a better OS prognosis (HR: 0.0919, 95%, CI: 0.0205-0.411, P < 0.001) than low IL-6 (HR: 0.205, 95%, CI: 0.063-0.665, P = 0.005) in the elraglusib/GnP treated patients. Correlations with mPFS were similar in the elraglusib/GnP patients for IL-6 (HR: 0.248, 95% CI: 0.072-0.848, P = 0.02) and IL-8 (HR: 0.297, 95%, CI: 0.111-0.743, P = 0.01). Conclusions: Preliminary results of our exploratory study identified low plasma levels of IL-6 and IL-8 prior to elraglusib/GnP treatment as potential predictive biomarkers associated with improved outcomes in previously untreated patients with mPDAC. The 1801 Part 3 Arm B clinical trial recruitment has been completed. We plan to analyze additional pre-dose plasma samples obtained from approximately 200 patients by April 2024. These will be analyzed using interim OS data available by April 2024 and included in the final presentation. Clinical trial information: NCT03678883 .